Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, September 12, 2017
Eisai and Mamorio to Jointly Launch "Me-Mamorio" Tracking Tool to Support People with Dementia and Seniors Going Out
Eisai Selected for Fifth Consecutive Year of Membership in Dow Jones Sustainability Asia Pacific Index 2017
Eisai Presents New Quality of Life Findings in Hepatocellular Carcinoma Patients from Lenvatinib Versus Sorafenib Study in Oral Session at ESMO Congress
Eisai Presents Results of Phase Ib/II Clinical Study of Lenvima (Lenvatinib) in Combination with Pembrolizumab for Renal Cell Carcinoma in Oral Session at ESMO 2017 Congress
Friday, September 8, 2017
Conclusion of Development Collaboration Agreement for Lenvima (Lenvatinib Mesylate) and Opdivo (Nivolumab) Combination Therapy for Treatment of Hepatocellular Carcinoma
Wednesday, September 6, 2017
Eisai Signs Agreement with Merck & Co. to Expand Enrollment of Combination Study for Lenvima (Lenvatinib) and Pembrolizumab Due to Encouraging Initial Data in Endometrial Carcinoma
Eisai Signs Agreement with Merck & Co. to Expand Enrollment of Study for Halaven (Eribulin) and Pembrolizumab Combination Due to Encouraging Initial Data in Triple-Negative Breast Cancer
Friday, September 1, 2017
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2017 Congress Three Abstracts on Lenvima (Lenvatinib) to be Presented in Oral Session
Thursday, July 27, 2017
U.S. FDA Approves Additional Use of Antiepileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures
Wednesday, July 26, 2017
Eisai Submits Simultaneous Applications in The United States and Europe for Lenvatinib in Hepatocellular Carcinoma

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: